Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Dtsch Med Wochenschr ; 139(15): 785, 2014 Apr.
Article in German | MEDLINE | ID: mdl-24691693

ABSTRACT

HISTORY AND ADMISSION FINDINGS: A 67-year-old male patient developed progressive renal failure following successful treatment of a soft tissue sarcoma that comprised surgical resection after neoadjuvant radiochemotherapy with the application of doxorubicin (cumulative dose 180 mg/m²) and ifosfamide (cumulative dose 33 g/m²). INVESTIGATIONS: Plasma creatinine concentration was elevated to 4.5 mg/dl. Upon detection of glucosuria and α1-microglobulinuria renal biopsy was performed. DIAGNOSIS, TREATMENT AND COURSE: Histologic analysis revealed massively injured tubules that could be explained by a toxic effect of ifosfamide. Glomeruli were not affected and appeared normal. After two months of conservative therapy, the patient developed an uremic syndrome requiring hemodialysis. Ever since kidney function did not recover albeit preserved diuresis. CONCLUSIONS: Ifosfamide can cause end-stage renal disease by a tubulotoxic effect that may be the result of a selective intracellular uptake into the proximal tubule via the human organic cation transporter 2 (OCT2).


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Kidney Failure, Chronic/chemically induced , Kidney Failure, Chronic/diagnosis , Sarcoma/drug therapy , Soft Tissue Neoplasms/drug therapy , Aged , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Diagnosis, Differential , Doxorubicin/adverse effects , Doxorubicin/therapeutic use , Humans , Ifosfamide/adverse effects , Ifosfamide/therapeutic use , Male , Sarcoma/complications , Soft Tissue Neoplasms/complications , Treatment Outcome
2.
Neuropathology ; 30(1): 92-6, 2010 Feb 01.
Article in English | MEDLINE | ID: mdl-19622110

ABSTRACT

Up to 8% of patients with gluten sensitivity (GS) develop neurological symptoms such as ataxia, dementia, seizures or peripheral neuropathy. The underlying immunological mechanisms still remain to be elucidated. We here report the case of a 68-year-old male patient suffering from progressive ataxia and dementia associated with chronic diarrhea and both elevated IgG and IgA antigliadin-antibodies. At autopsy, frequent argyrophilic glial and neuronal inclusions within the basal nucleus of Meynert were considered as the structural correlative for the cognitive decline. Significant neuronal loss in the cerebellar cortex and the inferior olives was accompanied by infiltrating CD8(+)/perforin(+)/granzyme B(+) cells as well as reactive astrogliosis and microglial activation. These CD8(+) cytotoxic T and NK cells are likely to act as effector cells responsible for neuronal cell death in patients with gluten sensitivity and neurological disease and might therefore at least partly be responsible for cerebellar symptoms in gluten ataxia. In conclusion, our results, showing an absence of B- or plasma cells but multiple CD8(+) as well as granzyme B and perforin expressing cells in ataxia-associated brain areas, suggest that there are also prominent cytotoxic effects in neuropathogenesis of GS.


Subject(s)
Ataxia/metabolism , Brain/metabolism , Celiac Disease/metabolism , Lymphocytes/metabolism , Aged , Astrocytes/pathology , Astrocytes/ultrastructure , Ataxia/diet therapy , Ataxia/pathology , Brain/pathology , Brain/ultrastructure , CD8 Antigens/metabolism , Celiac Disease/diet therapy , Celiac Disease/pathology , Cell Death , Cerebellum/metabolism , Cerebellum/pathology , Cerebellum/ultrastructure , Fatal Outcome , Gliosis/metabolism , Gliosis/pathology , Granzymes/metabolism , Humans , Killer Cells, Natural/metabolism , Killer Cells, Natural/pathology , Killer Cells, Natural/ultrastructure , Lymphocytes/pathology , Lymphocytes/ultrastructure , Male , Microglia/pathology , Microglia/physiology , Microglia/ultrastructure , Neurons/pathology , Neurons/ultrastructure , Olivary Nucleus/metabolism , Olivary Nucleus/pathology , Olivary Nucleus/ultrastructure , Perforin/metabolism , T-Lymphocytes/metabolism , T-Lymphocytes/pathology , T-Lymphocytes/ultrastructure
3.
Surgery ; 134(1): 72-9, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12874585

ABSTRACT

BACKGROUND: The aim of our study was to determine whether addition of the nitric oxide donor l-arginine at reperfusion may prevent the cardiopulmonary bypass (CPB)-induced vascular alterations in the intestine. METHODS: Twelve dogs underwent 90-minute hypothermic CPB. After 60 minutes, the cardiac arrest-treated group (n = 6) received 40 mg/kg intravenous bolus l-arginine, followed by 3 mg/kg/min infusion for 20 minutes. Hemodynamic parameters, blood gases, lactate, and glucose were monitored. Reactive hyperemia (RH) in response to superior mesenteric artery ischemia and vasorelaxation to systemically administered vasoactive drugs (acetylcholine [ACH] and sodium nitroprusside) were assessed before and after CPB and defined as percent change of vascular resistance. RESULTS: In the control group, CPB reduced reactive hyperemia (RH) (-26 +/- 15% vs -53 +/- 5%), and the response to ACH (-30 +/- 3% vs -42 +/- 7%). In the treated group, the post-CPB endothelial dysfunction was reversed (-37 +/- 1%, P <.05 vs control group) and RH partially recovered (-34 +/- 4%, P <.05). Administration of l-arginine resulted in a higher mesenteric oxygen delivery, increased nitrite/nitrate production, and lower lactate release from the mesenteric vascular circulation after reperfusion. CONCLUSIONS: CPB disrupts some of the regulatory functions of the endothelial cell in the mesenterium and these are mostly related to nitric oxide unavailability. Systemic supplementation of l-arginine at reperfusion prevents the CPB-induced mesenteric endothelial dysfunction in association with an increased blood distribution and a reduced metabolic impairment.


Subject(s)
Arginine/pharmacology , Cardiopulmonary Bypass/adverse effects , Nitric Oxide Donors/pharmacology , Splanchnic Circulation , Vasomotor System/physiopathology , Acetylcholine/pharmacology , Animals , Dogs , Endothelium, Vascular/physiology , Heart Arrest, Induced , Hemodynamics , Mesentery/metabolism , Nitric Oxide , Nitroprusside/pharmacology , Oxygen Consumption , Splanchnic Circulation/drug effects , Vascular Resistance , Vasodilation/drug effects , Vasodilation/physiology , Vasodilator Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...